Recession or not, these two utilities will keep delivering the electricity, natural gas, and water that make modern life possible.
The pharmaceutical stock soared after being approached for an acquisition, but has tanked in the weeks since management announced it has declined the offer.
Investors initially were displeased with full-year 2019 operating results, but shares have bounced back in February.
A failed study disappointed investors, but the company's pipeline should withstand the blow.
Investors continue to gobble up shares of the fast-growing company.
The speciality pharmaceutical company purchased the full rights to an important drug product.
Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.
Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.
GasLog offered mixed comments on the state of the market, announced major impairment charges, and slashed its distribution.
The healthcare company reported solid quarterly earnings and raised its fiscal full-year 2020 guidance.
The drug manufacturer is doubling down on biologic drugs to grow profits, but not all of the additional earnings will trickle down the income statement for individual investors.
The small-cap pharmaceutical company announced the pricing of a public stock offering.
What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.
The wind drought that plagued investors in 2018 and 2019 is likely over, but that's only one of the factors to consider.
A long-awaited and very important joint venture has been sidelined indefinitely. It could hurt investors in the long run.
Investors are coming around to the idea that global demand for lithium-ion batteries is about to pick up.
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
Another year, another set of financing transactions that provide a lifeline to the struggling company.
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.)